ELTXElicio Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $1.77 · now $1.77 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, ELTX has typically landed between $1.10 and $2.68 — a range of −37.9% to +51.1% from the issuance price $1.77.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

689 overlapping 1 month windows · 2023-11-13 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($1.77) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where ELTX has typically landed a month from the 2026-09-16 close of $1.77 — the range is history, not a prediction.

$1.1worst · -37.9%$2.68best · +51.1%
  • now $1.77 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $1.77 (+0.2%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $1.52–$2.03
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.1–$2.68
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 689 windows spanning 2023-11-13 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2026-06-12−79.1%−81.4%+0.0%
2026-06-10−78.7%−80.7%+3.8%
2026-06-09−78.1%−80.6%+4.6%
3 best
2024-03-06+113.8%+0.0%+113.8%
2024-03-07+93.7%+0.0%+98.0%
2024-03-13+93.1%−2.0%+93.9%

689 overlapping windows · 2023-11-13 – 2026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~3 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
33%
+10.3%
n=3
Feb
33%
+17.5%
n=3
Mar
33%
+14.5%
n=3
Apr
33%
+0.1%
n=3
May
67%
+13.5%
n=3
Jun
33%
−35.7%
n=3
Jul
67%
+8.2%
n=3
Aug
33%
−7.6%
n=3
Sep
67%
+0.6%
n=3
Oct
0%
−15.2%
n=2
Nov
100%
+10.1%
n=2
Dec
67%
+6.9%
n=3

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$15$2↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

37 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-08-31WILSON KAREN JdirectorAward / grant21,75021,750Form 4
2026-08-31RUFFOLO ROBERT RdirectorAward / grant21,75021,750Form 4
2026-08-31Ashe Carol GaildirectorAward / grant21,75021,750Form 4
2026-08-31ADAMS JULIANdirectorAward / grant21,75021,750Form 4
2026-08-31Chudnovsky YekaterinadirectorAward / grant21,75021,750Form 4
2026-08-31Nissenson AllendirectorAward / grant21,75021,750Form 4
2026-08-31Venkatesan JaydirectorAward / grant21,75021,750Form 4
2026-07-16Connelly RobertdirectorAward / grant186,944186,944Form 4
2026-07-16DeMuth PeterofficerAward / grant52,83252,832Form 4
2026-07-16Haqq ChristopherofficerAward / grant64,64364,643Form 4
2026-07-16Shah PreetamofficerAward / grant60,83360,833Form 4
2026-02-02Shah PreetamofficerAward / grant47,90047,900Form 4
2026-02-02Shah PreetamofficerAward / grant24,00024,000Form 4
2026-02-02DeMuth PeterofficerAward / grant41,60041,600Form 4
2026-02-02DeMuth PeterofficerAward / grant20,80021,543Form 4
2026-02-02Haqq ChristopherofficerAward / grant50,90050,900Form 4
2026-02-02Haqq ChristopherofficerAward / grant25,40057,381Form 4
2026-02-02Connelly RobertdirectorAward / grant147,200147,200Form 4
2026-02-02Connelly RobertdirectorAward / grant73,600120,570Form 4
2025-12-09DeMuth PeterofficerOption exercise362743Form 4
2025-12-09DeMuth PeterofficerOption exercise3620Form 4
2025-06-03Chudnovsky YekaterinadirectorAward / grant103,225103,225Form 4
2025-05-19Ashe Carol GaildirectorAward / grant7,9007,900Form 4
2025-05-19Chudnovsky YekaterinadirectorAward / grant7,9007,900Form 4
2025-05-19ADAMS JULIANdirectorAward / grant7,9007,900Form 4
2025-05-19RUFFOLO ROBERT RdirectorAward / grant7,9007,900Form 4
2025-05-19WILSON KAREN JdirectorAward / grant7,9007,900Form 4
2025-05-19Venkatesan JaydirectorAward / grant7,9007,900Form 4
2025-05-19Nissenson AllendirectorAward / grant7,9007,900Form 4
2025-04-15Shah PreetamofficerAward / grant191,624191,624Form 4
2025-03-05Chudnovsky YekaterinadirectorConversion3,500,5735,416,212Form 4
2025-03-05Chudnovsky YekaterinadirectorConversion3,442,3410Form 4
2025-02-03DeMuth PeterofficerAward / grant44,40044,400Form 4
2025-02-03Connelly RobertdirectorAward / grant121,600121,600Form 4
2025-02-03Haqq ChristopherofficerAward / grant44,00044,000Form 4
2024-12-16DeMuth PeterofficerOption exercise381381Form 4
2024-12-16DeMuth PeterofficerOption exercise3810Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.